(XNPT) (XNPT) Stock Price, News & Analysis

Company Overview

XenoPort, Inc. is a biopharmaceutical company. The Company is focused on commercializing HORIZANT (gabapentin enacarbil) Extended-Release Tablets in the United States. The Company's segment is the development and commercialization of product candidates for the treatment of neurological and other disorders. Its development-stage product candidates include XP23829, XP21279 and arbaclofen placarbil. HORIZANT has been approved by the United States Food and Drug Administration for the treatment of moderate-to-severe primary restless legs syndrome in adults and for the management of postherpetic neuralgia in adults. XP23829 is a fumaric acid ester compound and a prodrug of metabolite monomethyl fumarate being developed for the treatment for patients with moderate-to-severe chronic plaque-type psoriasis and/or patients with relapsing forms of multiple sclerosis. XP21279 is a Transported Prodrug of levodopa being developed for the treatment for patients with idiopathic Parkinson's disease.

Key Stats

• Today's Range: $7.07 to $7.07
• 50-Day Range: N/A
• 52-Week Range: $3.35 to $7.86
• Volume: N/A
• Average Volume: 1.22 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

XNPT Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of (XNPT) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that (XNPT) investors own include Bristol Myers Squibb (BMY), Netflix (NFLX), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), Ionis Pharmaceuticals (IONS), Supernus Pharmaceuticals (SUPN) and XOMA Royalty (XOMA).

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:XNPT
• CIK: 1130591
• Web: www.xenoport.com
• Phone: +1-408-6167200
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A